BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30592434)

  • 1. Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis.
    Zhang W; Kuang P; Liu T
    Ann Med; 2019 Feb; 51(1):28-40. PubMed ID: 30592434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia.
    Agarwal M; Bakhshi S; Dwivedi SN; Kabra M; Shukla R; Seth R
    Pediatr Blood Cancer; 2018 Jun; 65(6):e27001. PubMed ID: 29446543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients.
    Iacobucci I; Ferrari A; Lonetti A; Papayannidis C; Paoloni F; Trino S; Storlazzi CT; Ottaviani E; Cattina F; Impera L; Abbenante MC; Vignetti M; Vitale A; Potenza L; Paolini S; Soverini S; Pane F; Luppi M; Foà R; Baccarani M; Martinelli G
    Clin Cancer Res; 2011 Dec; 17(23):7413-23. PubMed ID: 22134481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletion of CDKN2A/B is associated with inferior relapse free survival in pediatric B cell acute lymphoblastic leukemia.
    Kathiravan M; Singh M; Bhatia P; Trehan A; Varma N; Sachdeva MS; Bansal D; Jain R; Naseem S
    Leuk Lymphoma; 2019 Feb; 60(2):433-441. PubMed ID: 29966470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.
    Ribera J; Morgades M; Zamora L; Montesinos P; Gómez-Seguí I; Pratcorona M; Sarrà J; Guàrdia R; Nomdedeu J; Tormo M; Martínez-Lopez J; Hernández-Rivas JM; González-Campos J; Barba P; Escoda L; Genescà E; Solé F; Millá F; Feliu E; Ribera JM;
    Cancer; 2015 Nov; 121(21):3809-17. PubMed ID: 26194343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic CDKN2A/2B deletions in adult Ph
    Pfeifer H; Raum K; Markovic S; Nowak V; Fey S; Obländer J; Pressler J; Böhm V; Brüggemann M; Wunderle L; Hüttmann A; Wäsch R; Beck J; Stelljes M; Viardot A; Lang F; Hoelzer D; Hofmann WK; Serve H; Weiss C; Goekbuget N; Ottmann OG; Nowak D
    Blood; 2018 Mar; 131(13):1464-1475. PubMed ID: 29348129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
    J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951.
    Mirebeau D; Acquaviva C; Suciu S; Bertin R; Dastugue N; Robert A; Boutard P; Méchinaud F; Plouvier E; Otten J; Vilmer E; Cavé H;
    Haematologica; 2006 Jul; 91(7):881-5. PubMed ID: 16818274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion analysis of p16(INKa) and p15(INKb) in relapsed childhood acute lymphoblastic leukemia.
    Graf Einsiedel H; Taube T; Hartmann R; Wellmann S; Seifert G; Henze G; Seeger K
    Blood; 2002 Jun; 99(12):4629-31. PubMed ID: 12036898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study.
    Kim M; Yim SH; Cho NS; Kang SH; Ko DH; Oh B; Kim TY; Min HJ; She CJ; Kang HJ; Shin HY; Ahn HS; Yoon SS; Kim BK; Shin HR; Han KS; Cho HI; Lee DS
    Cancer Genet Cytogenet; 2009 Nov; 195(1):59-65. PubMed ID: 19837270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia.
    Wang HP; Zhou YL; Huang X; Zhang Y; Qian JJ; Li JH; Li XY; Li CY; Lou YJ; Mai WY; Meng HT; Yu WJ; Tong HY; Jin J; Zhu HH
    Am J Hematol; 2021 Mar; 96(3):312-319. PubMed ID: 33306218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profiling refines minimal residual disease-based prognostic assessment in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.
    Ribera J; Zamora L; Morgades M; Vives S; Granada I; Montesinos P; Gómez-Seguí I; Mercadal S; Guàrdia R; Nomdedeu J; Pratcorona M; Tormo M; Martínez-Lopez J; Hernández-Rivas JM; Ciudad J; Orfao A; González-Campos J; Barba P; Escoda L; Esteve J; Genescà E; Solé F; Feliu E; Ribera JM; ;
    Genes Chromosomes Cancer; 2019 Nov; 58(11):815-819. PubMed ID: 31340073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols.
    Ampatzidou M; Papadhimitriou SI; Paisiou A; Paterakis G; Tzanoudaki M; Papadakis V; Florentin L; Polychronopoulou S
    Diagnostics (Basel); 2023 Apr; 13(9):. PubMed ID: 37174980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IKZF1
    Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
    J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia.
    Genescà E; Lazarenkov A; Morgades M; Berbis G; Ruíz-Xivillé N; Gómez-Marzo P; Ribera J; Juncà J; González-Pérez A; Mercadal S; Guardia R; Artola MT; Moreno MJ; Martínez-López J; Zamora L; Barba P; Gil C; Tormo M; Cladera A; Novo A; Pratcorona M; Nomdedeu J; González-Campos J; Almeida M; Cervera J; Montesinos P; Batlle M; Vives S; Esteve J; Feliu E; Solé F; Orfao A; Ribera JM
    J Hematol Oncol; 2018 Jul; 11(1):96. PubMed ID: 30041662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Genomic Landscape of PAX5, IKZF1, and CDKN2A/B Alterations in B-Cell Precursor Acute Lymphoblastic Leukemia.
    Ou Z; Sherer M; Casey J; Bakos HA; Vitullo K; Hu J; Friehling E; Gollin SM; Surti U; Yatsenko SA
    Cytogenet Genome Res; 2016; 150(3-4):242-252. PubMed ID: 28214896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and prognostic effects of
    Xia L; Zhang W; Gao L
    Biomarkers; 2019 Nov; 24(7):700-711. PubMed ID: 31382782
    [No Abstract]   [Full Text] [Related]  

  • 18. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
    Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
    Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of BCR-ABL1 isoforms on the prognosis of Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A meta-analysis.
    Zhang W; Kuang P; Liu T
    PLoS One; 2020; 15(12):e0243657. PubMed ID: 33338050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis.
    Zhang W; Kuang P; Li H; Wang F; Wang Y
    Ann Hematol; 2017 Feb; 96(2):215-225. PubMed ID: 27815723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.